Roche is not moving forward with its early-stage treatment candidate for Angelman syndrome, the company confirmed to Endpoints News, after advocacy groups posted about the halt on Wednesday.
The Swiss drugmaker notified patients on Wednesday that it has “initiated a search” for an external party to take over work on its investigational Angelman syndrome drug rugonersen, an antisense oligonucleotide. The study’s principal investigators are informing participating families, the company said, and the drug can be made available to them until February of next year.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters